HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.2%

Neg 0% Neu 89.2% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.